Concepedia

Author

Gabriele Antonarelli

European Institute of OncologyORCID

Also Known As

Antonarelli, Gabriele, G. Antonarelli, Gabriele Antonarelli

70

Publications

748

Citations

15

H-Index

21

Concepts

All Affiliations

European Institute of OncologyUniversity of MilanHospital Universitario Ramón y CajalUniversity Hospital HeidelbergFondazione IRCCS Istituto Nazionale dei Tumori
GA

About

Gabriele Antonarelli is an author at European Institute of Oncology specializing in medicine, cancer therapeutics, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

100

2

Cancer Therapeutics

3

3

100

3

Pathology

2

2

89

4

Health Sciences

1

1

11

5

Immunology

1

1

11

Gabriele Antonarelli

×

7

Publications

169

Citations

7

H-Index

YearCitations

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial

José Manuel Pérez-García, Javier Cortés, Manuel Ruíz‐Borrego,

The Lancet

2024

69

Myeloid cell‐based delivery of IFN‐γ reprograms the leukemia microenvironment and induces anti‐tumoral immune responses

Adele Mucci, Gabriele Antonarelli, Carolina Caserta,

EMBO Molecular Medicine

2021

28

Continuous sunitinib schedule in advanced platinum refractory thymic epithelial neoplasms: A retrospective analysis from the ThYmic MalignanciEs (TYME) Italian collaborative group

Gabriele Antonarelli, Chiara Corti, Paolo Andrea Zucali,

European Journal of Cancer

2022

20

Investigational immunomodulatory drugs for enhancement of triple negative breast cancer (TNBC) immunotherapy: early phase development

Paolo Tarantino, Gabriele Antonarelli, Liliana Ascione,

Expert Opinion on Investigational Drugs

2021

15

Comparison of real-world data (RWD) analysis on efficacy and post-progression outcomes with pembrolizumab plus chemo vs chemo alone in metastatic non-squamous non-small cell lung cancer with PD-L1 < 50%

Ilaria Attili, Carmine Valenza, Celeste Santoro,

Frontiers in Oncology

2022

14

Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

María Gión, Isabel Blancas, Patricia Cortez-Castedo,

Nature Medicine

2025

12

Safety of COVID-19 mRNA Vaccines in Patients with Cancer Enrolled in Early-Phase Clinical Trials

Pamela Trillo Aliaga, Dario Trapani, José Luís Sandoval,

Cancers

2021

11

Page 1